160 results about "Iothalamate Meglumine" patented technology

The present invention relates to methods and compositions for the treatment of skin-related conditions and disorders. In one aspect, the invention features methods and compositions for the transdermal delivery of compounds for the treatment of skin-related conditions and disorders, wherein the compositions include meglumine and a liposome component.

The ginkgo leaf powder for injection contains ginkgo extractive 1 weight portions, hydroxypropy1 betacyclodextrin 1-4 weight portions and pH regulator meglumine or sodium bicarbonate 0.02-0.08 weight portions. The preparation process includes mixing ginkgo extractive, hydroxypropy1 betacyclodextrin and pH regulator; filtering and ultrafiltering with 50000-150000 dalton ultrafiltering film; and direct bacteria-free freeze drying or spray drying of the ultrafiltered liquid to obtain the powder for injection. The said preparation process of the present invention can maintain fully the effective components while eliminating macro molecules, pyretogen, particle, microbe and other impurities to raise the safety and stability of the preparation obviously.

The present invention discloses one kind of bilobalide powder for injection and features its composition including bilobalide, meglumine and hydroxypropyl-beta-cyclodextrin in the weight ratio of 1 to 0.2-0.5 to 6-9. The present invention also discloses the preparation process of the bilobalide powder for injection. The bilobalide powder for injection has supplementary material capable of dissolving bilobalide completely without destroying its structure, and bilobalide as the main material is slightly soluble in water and easily soluble in acetone. The key point of the present invention is to select hydroxypropyl-beta-cyclodextrin as the solubilkizing supplementary material to raise the solubility of bilobalide greatly, and this raises the bioavailability of bilobalide and the curative effect of the injection greatly.

The invention provides sacubitril derivatives and medicine compositions, preparation methods and application thereof and belongs to the fields of medicine compounds and preparation thereof. The sacubitril derivatives comprise sacubitril lithium salt, sacubitril kali salt, sacubitril magnesium salt, sacubitril calcium salt, sacubitril strontium salt, sacubitril zinc salt, sacubitril ferric salt, sacubitril ammonium salt, sacubitril diethylamine salt, sacubitril ethylenediamine salt, sacubitril piperazine salt, sacubitril N-(2-ethoxyl)-pyrrolidine salt, sacubitril choline salt, sacubitril cholamine salt, sacubitril diethanol amine salt, sacubitril triethanolamine salt, sacubitril tromethamine salt, sacubitril meglumine salt, sacubitril diisopropylamine salt, sacubitril tert-butylamine salt, sacubitril N, N'-bis-benzyl ethylenediamine salt, sacubitril L-lysine salt, sacubitril L-arginine salt or sacubitril L-histidine salt.

This invention pertains to pharmaceutical compositions comprising certain carbamic acid compounds (e.g., which inhibit HDAC (histone deacetylase) activity) (e.g., PXD-101, N hydroxy-3-(3-phenylsulfamoyl-phenyl)-acrylamide)) and one or more additional ingredients selected from cyclodextrin, arginine, and meglumine. The present invention also pertains to the use of such compositions, for example, in the inhibition of HDAC, and in the treatment of conditions mediated by HDAC, cancer, proliferative conditions, psoriasis, etc.

Lansoprazole is a second generation proton pump inhibitor developed by Takeda in Japan, and is clinically and widely applied for treatment of acid related diseases and helicobacter pylori eradiation. The invention provides a preparation method of a Lansoprazole lyophilized powder injection preparation, creatively screens and tests the composition and dosage as well as the technology of the Lansoprazole lyophilized powder injection, obtains the optimal experiment condition, and gains good effect. The weight ratio of all the components of the Lansoprazole lyophilized powder injection satisfies the relation that Lansoprazole: meglumine: mannitol: sodium hydroxide equals to 30:10:60:4-4.1, the optimal weight ratio of all the components meets the relation that Lansoprazole: meglumine: mannitol: sodium hydroxide equals to 30:10:60:4.

The invention relates to a pharmaceutical composition containing high concentration of polydatin and process for preparation, wherein the composition comprises polydatin, meglumine and / or cyclodextrin, and other pharmaceutically acceptable auxiliary materials and carriers. The composition can be polydatin aqueous solution, or the lyophilized product prepared into aqueous solution before use. In the aqueous solution, the concentration of polydatin is not lower than 5mg/ml.

The freeze dried Lansoprazole sodium sdinjection has Lansoprazole sodium as active component and mannitol or meglumine as excipient in the weight ratio of 15-30 g to 5-50 g. The preparation process of the freeze dried Lansoprazole sodium injection includes the following steps: dissolving Lansoprazole sodium in 15-30 g in injection water of 200-400 ml, dissolving mannitol or meglumine as excipient in 5-50 g in injection water of 100-300 ml, mixing the two kinds of obtained solutions and adding injection water to 2000-3000 ml, adding active carbon in 0.5-1.5 g, filtering with microporous filter membrane, packing in vial, freeze drying under bacteria-free condition, and pressing cap. The freeze dried Lansoprazole sodium injection is used clinically in intravenous drip or intramuscular injection to treat peptic ulcer and other diseases.

The invention belongs to the technical field of medicinal preparation, and in particular relates to a telmisartan tablet composition. The telmisartan tablet composition is characterized by being prepared from 80 parts of telmisartan, 6.72 parts of sodium hydroxide, 24 parts of meglumine, 250 to 280 parts of sorbierite, 58 to 88 parts of calcium hydrophosphate, 20 parts of polyvidone and 10 parts of magnesium stearate. By selecting and using the combination of sorbierite and calcium hydrophosphate as filler, the composition can obviously improve the stability of the preparation and is favorable for production and application of the preparation.

The invention relates to lansoprazole composition freeze-dried powder for injection. The lansoprazole composition freeze-dried powder is characterized by comprising lansoprazole used as a main material, meglumine, mannitol, sodium hydrogensulfite and ethylene diamine tetraacetic acid, wherein the proportion of the components is 3:(0.1-1):(1-20):(0.01-0.5):(0.01-0.5); preferably, the proportion is 3:(0.5-1):(10-20):(0.1-0.3):(0.05-0.3); and more preferably, the proportion is 3:1:20:0.2:0.2. The preparation method comprises the following steps of: dissolving the raw material and the auxiliary materials by adding water; regulating the pH value; adding active carbon for decolorizing; filtering for decarburizing; fine filtering by using a filter membrane; sub-packaging; cooling to -50 to -46 DEG C according to a speed of 1-1.2 DEG C/minute; preserving heat and freezing for 3 hours; vacuumizing to 15Pa; uniformly heating up to -22 to -18 DEG C within 7-9 hours and then preserving heat for 1-2 hours; uniformly heating up to 3-7 DEG C within 4-6 hours and then heating up to 40 DEG C within 4 hours; preserving heat and drying for 3 hours; and packaging and storing after inspection.

Stabilized pharmaceutical solid composition of ACE inhibitor comprising an ACE inhibitor and a selective dosage formulation thereof comprising of meglumine. The ACE inhibitor selectively combined with a dosage form including essentially the meglumine is surprisingly found to avoid the degradation of ACE inhibitor by such dosage forms especially the commonly used pharmaceutical excepients. In particular, the presence of the meglumine in the dosage form for the active along with the active ACE inhibitor surprisingly avoid the degradation of the ACE inhibitor due to a) cyclization via internal nucleophilic attack to form substituted diketopiperazines, b) hydrolysis of the side chain ester group, and c) oxidation to form products having often unwanted coloration.

The invention relates to an adenosine monophosphate meglumine injection and a preparation method thereof. The preparation process is to take an appropriate amount of water for injection, add sodium chloride, cyclic adenosine monophosphate, and meglumine, stir to dissolve completely, add 0.05-0.2% (W/V) activated carbon for needles by volume, and stir for 15-30 minutes. Filter to remove carbon, add water for injection to nearly full amount, use phosphate buffer to adjust the pH value to between 6.0 and 6.5, add water for injection to the full amount, and check that the semi-finished product is qualified, filter, potting (full nitrogen gas in the whole process), and extinguish Bacteria, light inspection, packaging. The method has the advantages of selecting appropriate solvents and additives, improving the solubility and stability of meglumine cyclic adenosine monophosphate, and adopting a terminal sterilization preparation method to effectively ensure the sterility assurance level of the drug. The invention has the characteristics of formula composition, simple process, low production cost, strong drug stability and safety, and the like.

The invention provides a method for synthesizing flunixin meglumine. According to the method, reaction is carried out in a manner that 2-chloronicotinic acid and 2-methyl-3-trifluoromethylaniline serve as raw materials, water serves as a solvent and cupric oxide and para-toluenesulfonic acid serve as catalysts. According to the method, on the premise that the condition that para-toluenesulfonic acid serves as a catalyst is reported in the existing literature, cupric oxide is added, so that the catalysis efficiency is increased greatly, the reaction can be carried out efficiently, the reaction time is shortened, and the yield is increased; obtained flunixin and meglumine are salified in an acetonitrile solvent and are recrystallized, so as to obtain flunixin meglumine, and the total yield is about 90%; through synthesizing flunixin meglumine by the method, the operation is convenient and simple, and the requirements for equipment are low, so that the method is applicable to industrial large-scale production.

The invention relates to pharmaceutical composition containing a quinoline derivative or salt of the quinoline derivative, in particular to pharmaceutical composition containing 4-[3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy]-7-methoxy-6-quinolinecarboxamide or pharmacologically acceptable salt and basic amino acid or meglumine and/or at least one compound selected from potassium carbonate and potassium bicarbonate. The pharmaceutical composition has the characteristics of being high in dissolving-out rate and good in stability.

The invention provides a meloxicam injection for treating rheumatoid arthritis and osteoarthritis and a preparation method thereof. Every 1,500ml of injection comprises the following components in: 7.0-20g of meloxicam, 5-9.45g of meglumine, 20-150g of polyethylene glycol-400, 20-75g of poloxamer, 3-9g of glycine, 1.5-5.25g of sodium chloride and 0.225-2.25g of sodium hydroxide. The preparation method comprises the following steps: adding 1,000ml of injection water in a preparation tank, adding meloxicam, meglumine, polyethylene glycol-400, poloxamer, sodium chloride, glycine and sodium chloride; dissolving, and adding meloxicam; heating to 80 DEG C, and stirring for dissolving the meloxicam; adding 0.05g of needle activated carbon; stirring and adsorbing, and performing coarse filtration to remove charcoal; adding injection water to 1,500ml, and filtering with a 0.45mu m filter membrane until the mixture is clear; pouring into an ampoule, and sterilizing. The meloxicam injection has the active effects of quick absorption and high bioavailability, is not affected by pH, enzyme, foods and the like in the digestive tract, and has greatly increased curative effect.

The invention relates to a preparation method for 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid. Specifically, the method uses a recrystallization method to obtain a high-purity compound represented by a formula I shown in the description, and further, meglumine and Gd2O3 are complexed with the compound represented by the formula I to obtain the gadoteric acid meglumine. The method disclosed by the invention is simple to operate, has low costs, and is green, environmentally friendly and suitable for large-scale production.

The invention relates to a calcitriol injection and a preparation method thereof. The injection is prepared from the following ingredients in percentage by weight: 0.0005% of calcitriol, 1.2-1.6% of meglumine, 18-24% of polyethylene glycol 400, 1.2-1.7% of polyethylene glycol 6000, 0.1% of antioxidant, an appropriate amount of isotonicity regulator and the balance of water for injection. According to the injection, the content of calcitriol is remarkably increased, so that the drug dosage is reduced; and the stability of calcitriol to light and air is improved, and the bioavailability of calcitriol is also remarkably improved.

The synthesis and extraction and refine method for meglumine flunixin comprises: with p-toluenesulfonic monohydrate as catalyst and 20% KOH as extract, selecting 2-methyl-3- (trifluoromethyl) aniline and 2-chloronicotioyl by mole ratio as 2:1 for reaction with end pH value more than 11.5; cooling and crystallizing the residual aniline to separate and recover; using methanol in extraction and purification for flunixin; static cooling and crystallizing, and separating and cleaning the crystal to obtain the refined product; finally, recrystallizing to prepare the flunixin methylglucamine in water. This invention has high yield.

The invention relates to a method for refining a delafloxacin intermediate compound shown in a formula I. The method comprises the following steps: dissolving the compound in the formula I in a good solvent, mixing the compound with a poor solvent, heating a mixture and stirring the mixture, cooling the mixture for devitrification, and separating the mixture for crystallization. The refined compound in the formula I is hydrolyzed to obtain the high-purity delafloxacin, the high-purity delafloxacin and meglumine are subjected to a reaction to generate the delafloxacin meglumine salt, and the purity of the delafloxacin meglumine salt is greater than 99.5%. The method can effectively remove the impurity, an introduced solvent and an introduced reagent are little, yield is high, the process operation is simple, and the preparation cost is effectively reduced.